NCT00710372View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

November 30, 2010

Conditions
Mild Essential HypertensionModerate Essential Hypertension
Interventions
BIOLOGICAL

CYT006-AngQb

s.c. injection

Trial Locations (1)

CH-8952

Cytos Biotechnology (Sponsor's Headquarter), Schlieren

Sponsors
All Listed Sponsors
lead

Cytos Biotechnology AG

INDUSTRY